@misc{indiciaed70752cb5b35,
  title = {DESTINY-Lung06: trastuzumab deruxtecan and pembrolizumab as first-line treatment for HER2-overexpressing, PD-L1 TPS\&\#x2009;<50\% NSCLC.},
  author = {Pasi A J\&\#xe4;nne and Cai-Cun Zhou and Egbert F Smit and Enriqueta Felip and George Blumenschein and Koichi Goto and William N William and Chihiro Abe and Jie Lin and Chun-Yen Cheng and Kaline Pereira},
  year = {2026},
  doi = {10.1080/14796694.2026.2724696},
  url = {https://pubmed.ncbi.nlm.nih.gov/42682104/},
  note = {Source identifier: 42682104}
}